Michael S. Weiss


Michael Weiss earned his J.D. from Columbia Law School and his B.S. in Finance from The University at Albany. He began his professional career as a lawyer at Cravath, Swaine & Moore. From 1993 through 1999, he worked with Dr. Rosenwald in managing Paramount Capital/Aries Funds. In 1999, Mr. Weiss founded Access Oncology which was later acquired by Keryx Biopharmaceuticals (NASDAQ: KERX) in 2004. Following the merger, Mr. Weiss remained as CEO of Keryx until 2009 and grew Keryx to close to a $1BB market capitalization company at its peak. While at Keryx, he raised over $150MM in equity capital through public and private offerings, in-licensed Zerenex, Keryx’s iron-based Phosphate binder, which recently reported its second positive Phase 3 clinical trial, executed a $100MM+ strategic alliance with JT/Torii for Japanese rights to Zerenex, negotiated multiple SPA agreements with the FDA and managed multiple large clinical trials.

Lindsay A. Rosenwald , M.D.


Dr. Rosenwald earned his M.D. from Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University. He has founded over 50 companies during his 20+ year career in biotechnology, including most recently co-founding and selling Cougar Biotechnology to Johnson & Johnson for just under $1BB. He managed the Aries Funds from 1994 through 2007, with peak assets under management in 2000 of over $1BB dedicated to healthcare investments.From 2002 through 2006 he managed the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.

Sean Power, Chief Financial Officer
Lung Yam, M.D., Ph.D., Senior Analyst
Michael Kranz, Research Associate
Hari Miskin, Research Associate
William Lewis, Research Associate
Jenna Bosco, Director, Marketing & Investor Relations

Opus Point Partners

2 Gansevoort, 9th floor
New York, NY 10014
Main: 212. 554. 4504